Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with cholesterol levels not controlled on ongoing stable statin treatment~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L)~* Triglycerides \>350 mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25 mg/day AVE5530 (Type: EXPERIMENTAL): None
- 50 mg/day AVE5530 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).